Partial Heart Transplantation Breakthrough Offers Growing Valve Solutions for Thousands of Pediatric Patients

Dr. Joseph Turek debuts a partial heart transplant technique that uses donor valves to grow with pediatric patients, reducing the need for repeat surgeries.

By: AXL Media

Published: Apr 24, 2026, 6:40 AM EDT

Source: Information for this report was sourced from EurekAlert!

A Paradigm Shift in Pediatric Valve Replacement

A surgical advancement known as partial heart transplantation is set to redefine the standard of care for the hundreds of thousands of children globally suffering from severe heart valve disease. Presented by Dr. Joseph Turek at the International Society for Heart and Lung Transplantation annual meeting in Toronto, this technique focuses on replacing only the defective valves and supporting structures rather than the entire organ. Unlike mechanical or prosthetic options, these transplanted biological valves possess the unique ability to grow with the child. This development addresses a critical failure in traditional pediatric cardiology, where artificial valves remain static in size while the young patient’s body continues to develop.

The Domino Effect of Organ Utilization

The innovation relies on a "domino" strategy that harvests structurally sound valves from hearts that have been removed due to muscle failure or coronary issues. According to Dr. Turek, a pediatric heart transplant surgeon at Duke University, many hearts replaced during standard transplantation contain perfectly functional valves that were previously discarded. By salvaging these components, the medical community could theoretically obtain two viable valves from every traditional heart transplant performed. With approximately 5,000 heart transplants occurring annually in the United States, this method has the potential to generate thousands of new grafts, significantly easing the chronic shortage of pediatric donor tissue.

Immune Tolerance through Thymus Integration

Beyond the physical structure of the valve, researchers are pioneering heart–thymus co‑transplantation to address the lifelong challenge of organ rejection. This technique, developed at Duke University, involves transplanting cultured thymus tissue alongside the cardiac components to essentially "reprogram" the recipient’s immune system. By introducing donor thymus tissue, clinicians aim to induce a state of immune tolerance that allows for drastically reduced doses of immunosuppression drugs. Dr. Turek noted that for children with specific immune deficiencies, this combined approach could eventually eliminate the need for toxic anti‑rejection medications entirely, thereby extending the long‑term survival of the transplanted grafts.